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Abstract
The human olfactory system recognizes a broad spectrum of odorants using approximately 400 different olfactory receptors
(hORs). Although significant improvements of heterologous expression systems used to study interactions between ORs
and odorant molecules have been made, screening the olfactory repertoire of hORs remains a tremendous challenge. We
therefore developed a chemical systems level approach based on protein-protein association network to investigate novel
hOR-odorant relationships. Using this new approach, we proposed and validated new bioactivities for odorant molecules
and OR2W1, OR51E1 and OR5P3. As it remains largely unknown how human perception of odorants influence or prevent
diseases, we also developed an odorant-protein matrix to explore global relationships between chemicals, biological targets
and disease susceptibilities. We successfully experimentally demonstrated interactions between odorants and the
cannabinoid receptor 1 (CB1) and the peroxisome proliferator-activated receptor gamma (PPARc). Overall, these results
illustrate the potential of integrative systems chemical biology to explore the impact of odorant molecules on human
health, i.e. human odorome.
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Introduction
Commonly present in food, fragrance and cosmetic products,
odorants are volatile molecules that stimulate G-protein-coupled
olfactory receptors (ORs) located in the olfactory sensory neurons
of the nasal epithelium [1,2]. In human, it is estimated that
thousands of odorant molecules are recognized by around 400
different hORs [3]. Several studies have attempted to connect
odorant physicochemical properties to the olfactory perception;
however, odor coding remains largely unknown [4–9]. To
recognize odorant molecules, the olfactory system uses combina-
torial coding scheme to encode odor identities by different
combinations of ORs [10,11]. Indeed, it has been shown that
one odorant can interact with several different ORs and one OR
can be activated by a number of molecules. Although recent
optimizations in functional expression of ORs for the screening of
odorant compound libraries have been made [12], investigating all
combinations is still expensive, time consuming and remains
therefore a tremendous challenge. Up to now, only a small
number of experimental studies have identified odorant-OR
interactions in various organisms, mainly in mammals and insects
[13–19]. Despite some efforts to elucidate the link between
activation of ORs and odor perception, our understanding of
peripheral olfactory coding in mammals remains limited [11,20–
24].
Odorant molecules might, apart from their conventional and
primary role in olfaction, also trigger drug-target proteins relevant
in pharmacology. For instance, studies have suggested that odor
perception is involved in pathologies related to psychiatric
disorders as well as in food intake behavior [25,26]. Recently, a
direct functional link between the olfactory and hormonal systems
in humans has been reported [27]. Although promising, these
studies remain confined to a few molecules and to a limited
number of protein targets.
With the availability of large-scale chemical bioactivity data-
bases and the recent advances in chemoinformatics and bioinfor-
matics, it has become possible to include the chemical space in
systems biology, i.e. systems chemical biology [28]. In addition, the
application of global pharmacology profiles and network pharma-
cology of small molecules is emerging as a new paradigm in drug
discovery [29]. However, these concepts of multi targeting have
primarily been implemented for drugs [30] but not in the context
of environmental chemicals. This prompted us to investigate the
global network pharmacology of odorant molecules, in addition to
peculiar associations between odorant molecules and hORs. In
this study, we chose the term ‘‘odorome’’ to refer to the
interactions of odorant molecules with biological targets taken as
a whole.
We considered two fundamental challenges: the need for a
predictive method able to decipher the peripheral olfactory coding
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in humans, and the potential pharmacological implications
associated with odorants. Therefore, based on a newly established
systems biology procedure [31], a specific human protein-protein
association network (i.e. OR-OR network) linking ORs and
odorant molecules was developed, allowing for the discovery of
new odorant-OR interactions which subsequently may be tested.
New suggested interactions were confirmed experimentally for six
compounds and three human ORs. Further, we investigated
human diseases associated to ORs by integrating a high
confidence human interactome [32,33] in the protein-protein
association network developed in this context. It revealed several
new functional proteins and biological pathways influenced by
odorants. Lastly, we explored the potential pharmacological space
of odorant compounds based on a large chemogenomics database.
From the chemical structure of a large collection of odorant
molecules, annotations and predictions of the activity profile
against most known biological targets were gathered. The
previously unknown activity for two sets of three odorants was
evaluated and confirmed experimentally for the cannabinoid
receptor 1 (CB1) and for the peroxisome proliferator-activated
receptor gamma (PPARc). Thus, taking advantage of recent
progress in computational chemical biology, we are able to
propose new interactions, which are important for the under-
standing of the olfactory perception mechanism and – at the same
time – highlight targets and pathways recognized by odorant
compounds.
Materials and Methods
Odorant molecules data
We extracted 2,927 compounds, their chemical structures and
their respective flavor, odor or aroma descriptions from Flavor-
Base (FLB) version 2004 (http://www.leffingwell.com/flavbase.
htm). Flavor-Base is one of the most extensive collections of
compounds related to natural and synthetic flavoring chemicals.
All chemicals are listed on the U.S. Food and Drug Administration
(FDA) and Flavor and Extracts Manufacturers Association
(FEMA) Generally Regarded As Safe (GRAS) list. The flavor
and odor descriptions provided by Dr. J. Leffingwell and
Associates are also supported by several published studies sources
such as Arctander [34].
All the selected molecules possess at least one odorant
component described as ‘‘odor’’, ‘‘flavor’’, or ‘‘aroma’’, excluding
the molecule exclusively described as ‘‘taste’’. Existing variations in
organoleptic descriptions by various authors were taken into
consideration. Note that no information about interactions
between odorant molecules and ORs is provided in Flavor-Base.
For the set of compounds extracted, we compiled odorant
molecule-OR binding interactions from the literature and the
Olfactory Receptor Database (ORDB) [35] for human, rat and
mouse (Table S1 in File S1). Only direct physical interactions were
considered (i.e. binding data) and none of the gene expression was
kept in this study.
Human odorome
To create the human olfactory network, we developed a
protein-protein association network (defined as an OR-OR
network in this study). The OR-OR network was generated by
initiating a node for each human OR, and by linking any OR-OR
pair where at least one overlapping odorant was identified. To
reduce noise and select the most significant OR-OR associations,
we assigned a weighted score to each OR-OR association. The
weighted score was calculated as the sum of weights for shared
odorant molecules, where weights are inversely proportional to the
number of associated ORs for a given odorant as previously
described and thoroughly benchmarked against two gold standard
repositories [31]. The resulting human OR-OR associations
network contains 24 ORs connected via 463 associations.
In a second step, the human olfactory network was enriched
with rat and mouse odorant molecule-OR binding interactions
gathered previously. To do so, the non-human OR names were
translated into their human orthologous genes using YOGY [36]
For ORs that have no orthologous human gene, homology
searches were performed using BLASTP [37]. Human ORs with
the highest score and E-value associated to rat or mouse ORs were
integrated in the olfactory network represented by human
odorant-OR interactions. All OR names were converted to Gene
ID using UniProt [38]. In total, 83 ORs and 323 molecules with
binding information to at least one OR were collected and
integrated in the OR-OR network resulting in 938 unique
associations. It is important to notice that the discrimination
between ORs agonist and antagonist is not included in the study
and our network cannot be used to identify odorant synergies or
opposite effect on ORs.
Panels of odor descriptions were also associated to the molecules
using the Flavor-Base database. Therefore, we were able to
retrieve 189 odor for 230 odorant molecules among 323
compounds binding to OR proteins, and to map the odor
perceptions associated to chemicals in the OR-OR network.
Integrating odor descriptions into the human odorome
To evaluate the tendency and selectivity of odors associated to
ORs, we developed an association score (AS) based on the number
of compounds associated to an odor. The AS is calculated using
the equation:
AS~
A
B
 
|
A
C
  
|
B
D
 
,
where AS is the association score, A the number of molecules for
one OR, B the total number of compounds carrying one odor, C
the number of ORs for the same odor, and D the total number of
molecule-odor interactions. In our study D=4193. Table 1
presents an example of the results obtained for the odor ‘‘anis’’.
With this formula, we can associate a score between each odor
and each OR. The higher the score, the more significant is the
interaction. In this example, OR1G1 and OR52D1 are the most
significant association to the odor ‘‘anis’’.
Results for the four highest odors associated to each human OR
are shown in Table S2 in File S1.
Table 1. List of ORs predicted to interact with molecules
carrying the ‘‘anis’’ note.
Odor ORs Number of compounds (A) AS
anis OR1D2 2 1.59 10-4
anis OR1D20 3 3.57 10-4
anis OR1G1 5 9.93 10-4
anis OR52D1 5 9.93 10-4
anis OR5D18 4 6.36 -10-4
anis OR6A2 2 1.59 10-4
Total C = 6 B= 21
doi:10.1371/journal.pone.0093037.t001
Global Mapping of the Human Odorome
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Predicting novel hOR target for odorant molecules
A network protein procedure was generated to predict
interaction between hOR and odorants using the developed
human odorome. This network-neighbor’s pull down approach is
a three steps procedure: (a) selection of the input hORs: extraction
of the hORs known to be associated with the selected odorant
molecules from the available literature information. (b) Identifica-
tion of network(s) surrounding the input hORs by a neighbor
protein procedure. In this procedure, our odorome was queried for
the input ORs, and associations between them were compiled. For
each neighbor, a score was calculated taking into account the
topology of the surrounding network, based on the ratio between
total interactions and interactions with input ORs. (c) Establish-
ment of a confidence score for each OR: each of the pull down
complexes was tested for enrichment on our input set by
comparing them against 1.0e4 random complexes for OR-OR
association set to establish a score for each connected OR. The
score was used to rank ORs to select potential hORs targets for
odorants. The accuracy of this procedure was demonstrated
previously for known drugs and drug targets [31].
Integrating the human interactome and the odorome
Protein-protein interactions (PPIs) were extracted from a list of
ORs and their first interactor proteins using an in-house human
interactome network based on experimental data from human and
model organisms [32,33]. The current interactome contains
507,142 unique PPIs linking 14,441 human proteins. PPIs of the
83 ORs allowed extending the odorome to 183 genes. This
network was used for the disease and pathways enrichment
analysis. Human disease information was extracted from the
GeneCards database [39]. We also determined the enriched terms
among pathways using the KEGG and Reactome databases.
Protein-disease relationships and gene-pathway links were inde-
pendently evaluated in the odorome. P-values were calculated
using hypergeometric testing with Bonferroni adjustment for
multiple testing [40]. Results are shown in Table S3 in File S1.
Odor-target matrix
A chemogenomic database, ChemProt, was used to explore the
human pharmacological space with the FlavorBase odorant
compounds. ChemProt is a chemical genomics platform that
integrates chemical-protein interactions from various available
data sources [41]. The current version of ChemProt as of January
2013 contains 1,150,000 unique chemical structures with biolog-
ical information for more than 15,290 proteins [42]. We
considered only compounds with binding activity in this study.
Mapping odorant molecules in the pharmacological
space
Each chemical structure from FLB and ChemProt was encoded
into binary strings using the Molecular ACCess Systems keys
(MACCs) to investigate structural similarity between FLB com-
pounds and ChemProt chemicals. Using the Tanimoto coefficient
(Tc), the degree of similarity between two molecules was
quantified. Chemical-compound networks were generated to
visually display compounds from FLB having a high similarity
coefficient with ChemProt molecules using Cytoscape [43].
GloSensor cAMP assay
To validate predicted interactions between odorant compounds
and ORs or the CB1 receptor, we used the GloSensor cAMP assay
from Promega and measured the EC50 values of compounds. This
luminescent assay is a sensitive method for measuring Gs and Gi-
protein coupled receptor activation by real-time detection of
intracellular second messenger cAMP [44]. The protocol is
described in the GloSensor cAMP assays paragraph in the
Supplementary Methods (S_file).
Competitive PPARc binding assay and trans-activation
assay
To validate predictions of odorant-PPARc interactions, IC50
values for respective compounds were determined by competitive
binding using time-resolved fluorescence resonance energy trans-
fer (LanthaScreen, Invitrogen) on a Wallac EnVision (PerkinEl-
mer). Furthermore, to assess the bioactivities of the predicted
molecules, a PPARc lipid-binding trans-activation assay was used
(PPAR LBD). The protocols are described in details in Compet-
itive PPARc binding assay and PPAR-LBD Transactivation
paragraphs in the Supplementary Methods (S_file).
Results
To improve knowledge of olfactory perception and biological
roles of odors in human, odorant molecules were used to generate
a predictive model to identify odor coding, and to explore the
known pharmacological space. We integrated various data type
such high confidence protein-protein interactions and large
chemical biology database to underlie molecular mechanisms of
odorant molecules and the biological pathways they perturb.
Overall, the results show a global mapping of the human odorome.
The key steps of our approach are illustrated in Figure 1.
Modeling of the odorant human combinatorial coding
Generation of a human odorome. To explore the organi-
zation of the odor space in humans, i.e. how ORs respond to an
odorant, we compiled from the literature a list of carefully curated
chemical-OR interactions from human (Table S1 in File S1). In
total, we gathered 189 odorant molecules associated to 24 human
ORs through 463 interactions. We implemented the ‘‘target
hopping’’ concept i.e. if two proteins both bind to the same ligand,
they can be considered as interacting in the same chemical space
[45]. So, assuming that two ORs biologically activated with the
same molecule are likely to be involved in a common mechanism
of stimulation, we developed a protein-protein association network
for ORs (defined as an OR-OR network) in a similar manner as
described previously [31]. The OR-OR network, depicted in
Figure 2a, clearly shows that some ORs are highly connected such
as OR52D1 and OR1G1, whereas other ORs are sensitive to very
specific molecules only.
In addition, from the OR-OR network, we mapped the odor
perceptions associated to the chemicals (Figure 2b) integrating the
information from Flavor-Base and ORDB. Studies have reported
that chemicals having a similar odor profile may activate the same
receptors [11,23,46]. However, in our compilation the majority of
chemicals have multiple annotations with several odors e.g.
dihydrojasmone has fresh, fruity, jasmine and wood odors. Using
an association score (AS), we prioritized ORs to odors and
identified odor tendencies for a given receptor (for odor-OR
relationships see Table S2 in File S1). For example, our approach
depicts that OR1G1 is highly stimulated by fatty and waxy notes
[46]. Some general notes e.g. ‘‘fruity’’ appear to be connected to
many receptors. In opposite, quite few notes are linked to only one
OR i.e. ‘‘light’’, ‘‘ocean’’ and ‘‘clean’’ are related to OR1D2 and
‘‘medicine’’ and ‘‘phenol’’ are linked to OR1E3.
From the network, we can identify also hubs of ORs that are
more related to a given odor. For example, ‘‘muguet’’, a floral
odor, is exclusively reported to OR1D3, OR1D4, OR1D5 and
Global Mapping of the Human Odorome
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OR1D6, and ‘‘sour’’ odor is associated to OR51E1, OR117P and
OR51E2. Interestingly, although ‘‘pineapple’’ is associated to
OR51L1 and OR2C1, there is no connection between the two
ORs. In fact this OR-odor association comes from different
compounds that have not been tested on the same OR. Obviously,
the method is dependent of the diverse experiments performed so
far on ORs and reflects that some ORs have been tested more
than others. However, the network provides a global visualization
of the human odorome based on current knowledge.
Deciphering novel odorant molecule- hOR
interactions. An interesting aspect from the OR-OR network
is the possibility to suggest new odorant-OR interactions that were
not studied previously. Based on the assumption that if two ORs
are affected by two odorants, and one of the OR is further
deregulated by an additional odorant, it might be that both ORs
are in fact affected with the same three odorants as shown in
Figure 3. Using a neighbor protein procedure, an association score
between each OR and each odorant can be computed, as
described previously [31,32]. From, the developed network it is
then possible to evaluate the significance of the odorant-OR
association as well as to predict the association for new ligand-OR.
To assess the performance of our approach, we decided to test a
set of compounds experimentally. As we had bioassays for
OR2W1, OR5P3 and OR51E1, we focused on these 3 ORs for
the validation.
Citral and Citronellal, two compounds naturally produced in
the oil of various plants including lemongrass and orange, have
been shown to be strong agonists of OR1A1 [47]. These
compounds were reported to be also ligands of OR1A2 [47,48].
Based on the OR-OR network, these compounds show a strong
association score with these ORs but also may interact with
OR2W1 (Table 2). As the stimulation of OR2W1 by these two
compounds was not reported in the literature, we decided to test
this prediction experimentally using OR-transfected Hana3A cells
and a functional assay adapted to GPCR screening, the GloSensor
cAMP assay [44]. Citral and citronellal were found to activate
OR2W1 with EC50 values of 128.7 mM and 207.9 mM, respec-
tively (Fig. 4a). These odorants were about 4 to 6 fold less efficient
than benzylacetate, one of the best OR2W1 ligands
(EC50 = 34.7 mM) [13].
We also investigated the activation of other ORs by new
compounds (Figs. 4b, 4c). For example, from our OR-OR
network, we predicted that two new compounds, 1-octanol and
celery ketone (two OR1G1 ligands) might interact to OR5P3
(Table 2). Experimentally, we observed that both compounds
activate this receptor with EC50 values of 115 mM and 482.6 mM
respectively, which indicates that these odorants are as active as (-)-
carvone (EC50 = 387.6 mM), a known OR5P3 ligand [13].
Similarly, isovaleric acid and propionic acid (OR1G1 and
OR52D1 ligands) were identified as new putative ligands of
OR51E1 (Table 2) and tested experimentally. Isovaleric acid
activated OR51E1 in the same range as that observed for
nonanoic acid, a known ligand of this receptor (EC50 = 152.7 mM
and EC50 = 197.2 mM, respectively) [13]. Conversely, propionic
acid showed an activity 5 fold lower with an EC50 = 923.2 mM.
Finally, we should notice that the tested compounds did not induce
any response in mock-transfected cells. However, for some of the
Figure 1. Workflow of the study. Strategy to improve knowledge of olfactory perception and biological roles of odorant molecules. First an OR-
OR association network identifies novel odorant-OR interactions for odorant candidates. Second, pathways linked to proteins are integrated in the
OR-OR network allowing deciphering odor-disease connections. The last step involves scoring and ranking of odorant candidates for biological
targets within the pharmacological space.
doi:10.1371/journal.pone.0093037.g001
Global Mapping of the Human Odorome
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compounds, e.g. celery ketone and 1-octanol, no saturation could
be observed because of cytotoxic effects at concentrations higher
than 1023 M.
Linking the human odorome to diseases and pathways
To investigate dysfunctions and diseases associated with the
olfactory system, we enriched the developed OR-OR network by
integrating data gathered from mouse and rat (Table S1 in File
S1). Although the odor perception from one species to another one
might be different, OR orthologs tend to show conserved ligand
interactions [49].
ORs from rodents were linked to human orthologs resulting in a
total of 775 additional chemical-protein interactions (Table S4 in
File S1). Consequently, the new OR-OR network contained 938
interactions between 83 proteins (Fig. S1). We then integrated
protein-protein interactions (PPIs) into the human odorome, and
constructed a PPI network for the set of 83 human ORs. The
interactome used was a high confidence set of experimental PPIs
extracted from a compilation of diverse data sources [32,33]. A
total of 183 new genes were identified and among them, 12 were
connected to at least one of the 83 ORs with high confidence
scores. In general, ORs appear to interact with three guanine
nucleotide binding proteins: GNAL, GNGT1 and GNB1. OR1G1
is linked to a fourth protein, the odorant binding protein 2B
(OBP2B). In a second step, disease enrichment data were included
with the aim of prioritizing disease candidate genes. Among them,
three disease groups are statistically significantly connected:
hypertension, schizophrenia and mood disorders (list of genes
and p-values can be found in Table S3 in File S1). A previous
study has explored the potential of olfactory dysfunction as a key
component in early diagnostic strategies of Parkinson and
Alzheimer diseases [50]. The UPSIT (University of Pennsylvania
Smell Identification Test) revealed abnormality more frequently
for patients with neurological diseases than olfactory-evoked
responses (http://emedicine.medscape.com/article/861242-
overview). For hypertension, patients with smell impairment are
reported to use larger quantities of sugar and salt to highlight
flavors and thus increase the risk of developing hypertension [51].
We analyzed also the functional properties of the olfactory
system using two pathways repositories (KEGG and Reactome)
[52,53]. From the KEGG database, we observed statistical
significance for the calcium signaling pathway, the neuroactive
ligand-receptor interaction pathway, the taste transduction path-
way, the type 2 diabetes pathway and the long term depression
pathway. From the Reactome database, three pathways were
significantly linked to the global odorome, the ‘opioid signaling’,
the ‘integration of energy metabolism’ and the ‘GPCR signaling’
pathways.
A recent study supports our findings by showing that odor-
identification deficit and memory impairment are closely associ-
ated with disease-specific metabolic changes [54]. Similarly, it is
speculated that flavor molecules are suggested to play a role in
food intake and thus potentially increase prevalence of overweight
and obesity [55]. A possible mechanism to reduce food intake
could involve a perturbation of the opioid signaling pathways.
Overall, these biological networks revealed interesting function-
al properties and biological pathways involving known drug-
Figure 2. View and mapping of the odor in the OR-OR association. (a) View of the human odorome. Nodes and edges represent the human
ORs and the connections between the ORs, respectively. The node size corresponds to the number of odorant molecules known to bind to a
particular OR. A weighted score, represented by the width of the edges, was assigned to each OR-OR association. It represents the strength of the link
between two ORs as defined by the number of shared compounds for both ORs. (b) Mapping of odor descriptions on the human odorome using the
association score (AS). Odor(s) tendency for ORs were integrated into the human odorome map. (N.D. = non-determined odor for OR7D4).
doi:10.1371/journal.pone.0093037.g002
Figure 3. Schema of the OR-odorant prediction concept. In this example, C3 is an odorant predicted to bind to OR2 because is binding to OR1
like C1 and C2.
doi:10.1371/journal.pone.0093037.g003
Global Mapping of the Human Odorome
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targets. Such results imply that odorant molecules interact not only
with ORs but might also affect drug-targets.
Mapping the odorant pharmacological space
As a final step we investigated all biological targets potentially
recognized by odorant compounds. Chemical-protein interactions
for a complete biological system are usually unknown apart for
some drugs, and the majority of molecules have only been studied
for one or few protein targets. This is especially true in the case of
odorant compounds, which have been mostly studied on ORs.
We decided to identify potential novel and unexpected odorant-
protein interactions. Assuming that chemicals sharing highly
similar structure also share similar biological properties [56], we
used ChemProt, a large curated chemogenomic database of more
than 1 150,000 molecules with over two millions chemical-protein
interactions [41]. Using MACCs fingerprints and a strict
Tanimoto coefficient (Tc) distance threshold of 0.9, 1,091 odorants
were identified with odorant-protein interactions for 821 proteins.
Interestingly, for 329 odorants, links to 200 proteins were already
available (i.e. compounds tested for a protein), represented by 556
unique chemical-protein interactions. For example, capsaicin,
Figure 4. Concentration-response curves of odorants for human ORs. Odorants predicted as agonists ( = predicted compounds) and
odorants previously shown to be agonists by Saito et al. 2009 (positive controls) activated four human ORs: (a) OR2W1, (b) OR51E1 (c) OR5P3. Data
points and EC50 values are means 6 s.e.m. from at least three experiments.
doi:10.1371/journal.pone.0093037.g004
Global Mapping of the Human Odorome
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described in Flavor-Base with a ‘‘slight herbaceous odor’’ (known
also for its strongly perceived ‘‘burning hot pungent taste’’) has
shown agonist activity on the human vanilloid receptor 1 (TRPV1)
and inhibition of PTGS1, a well-known protein inhibited by non-
steroidal anti-inflammatory drugs such as aspirin. Another
example, thymol is activating a human transient receptor (TRPA1)
which has a central role in the pain response to endogenous
inflammatory mediators [57]. In order to reveal common
structural features between odorants and other molecules, we
visualized their distribution inside the chemogenomic database by
developing a chemical similarity network, excluding annotations
(Fig. S2). The generated network can be interpreted in two ways:
some odors (green) form large clusters, which appear to share
similar features with few chemicals from ChemProt (blue). For
instance, 2-heptyl-butyrate (wax, fruit, green, tropical, floral) is
structurally similar (Tc of 0.952) to the fatty acid isopropyl
palmitate, a solvent for fragrance agents and known to have
binding affinity to the human cannabinoid receptor 2 (CB2) [58].
Other odorants show structural similarity with molecules possess-
ing large set of bioactivities in ChemProt. This is the case with
theobromine, a cosmetic additive, similar to caffeine and
theophylline, two compounds intensively studied in healthcare
[59].
Based on Uniprot identifiers, the 821 proteins potentially
targeted by odorants were categorized into 285 families, and 26 of
them have more than 100 interactions with odorant molecules
(Fig. S3). Not surprisingly, the G-protein coupled receptor family
(GPCR), which contains ORs, is the most common type predicted.
A majority of odorant-GPCR associations are with cannabinoid
receptors (69%). Few other predictions are for metabotropic
glutamate receptors (2%) and opioid receptors (1%). Ligand-gated
ionic channel, amidase enzyme family, nuclear receptors and
cytochrome P450s are also families largely targeted by odorants
which is consistent with previous discovery linking the olfactory
system with ligand-gated ion channels and amidase [60,61].
We decided to investigate the interactions of odorants with the
human cannabinoid receptor CB1 using CB1-transfected
HEK293 cells and the GloSensor cAMP assay, because of its
large representation in predicted proteins as target, its role of
endocannabinoid system in metabolic diseases [62], and its
probable link with olfaction [63]. We first checked that our
experimental system worked efficiently by testing cannabinoids
acting as agonists (AEA, HU210) or inverse agonist (AM251) (Fig.
S4). Then, amongst the molecules predicted as CB1, we selected
two of them (i.e. tributyl-acetylcitrate and 2-phenylethyl hexano-
ate) due to their structural similarity with hexadecyl propanoate, a
known inhibitor of CB1 [58]. In addition, we looked on the
flexibility of the molecules able to map to the structure of
anandamide, a known natural CB1 ligand [58,61] and select the
compound 2-nonanone for testing. The three compounds,
tributyl-acetylcitrate, 2-nonanone and 2-phenylethyl hexanoate
were found to interact with the CB1 receptor although with a
weak EC50 (Figure 5). They elicited an increase in cAMP
production in control cells, this effect being blocked in pertussis
toxin-treated cells. These results indicate that the predicted
compounds acted as weak inverse agonists, with EC50 values
varying from 122 mM to 509 mM. All tested compounds did not
induce any response in mock-transfected cells.
We looked also into nuclear receptors and more specifically
PPARc, a target also associated to metabolic syndrome, inflam-
mation and type-2 diabetes. PPARc has shown an interesting
response to the application of nutrition-based interventions [64].
Indeed, it has been reported that naringenin, from grapefruit or
elderflower, stimulated PPARc transactivation making cells more
sensitive to insulin [64]. PPARc is also involved in the regulation
of fatty acid storage and glucose metabolism, and it has been
recognized that nutritional supplementation such as omega-3 fatty
acids and polyunsaturated fatty acids influence the inflammatory
response of some diseases such as inflammatory bowel disease
(IBD) [65]. Moreover, PPARc have been identified to interact
with endocannabinoid system [66]. We decided therefore to
investigate the interaction of odorants on the PPARc protein.
Among them, we considered naringenin, methyl c linolenate
and 2-phenylethyl salycilate that show structural similarity with
PPARc ligands (kaempferol, lauric acid methyls ester and
benzenepropanoic acid, 4-([1,19-biphenyl]-2-ylmethoxy) respec-
tively). Using a competitive PPAR binding assay, inhibition of
binding (IC50) values for three predicted compounds were
determined. Interestingly, all compounds showed binding activities
on PPARc at the mM scale, validating the multi-activities of
odorants in cellular processes other than olfaction (Figure 6a).
Compared to the reference molecule, rosiglitazone (IC50<50 nM
in this assay), naringenin shows good affinity to PPARc
(IC50 = 7.4 mM). The food additive phenylethyl salicylate present-
ed activities with the same range (IC50 = 9.2 mM) whereas methyl
c linolenate a fatty acid compound naturally present in banana,
grapefruit juice, grape, melon, strawberry, tomato and chicory
Table 2. Prediction of novel OR-odorant interactions.
Odorant Known OR Score* Predicted OR Score*
Citral OR1G1 0.171 OR2W1 0.889
OR52D1 0.171
OR1A1 0.358
OR1A2 0.748
Citronellal OR1G1 0.171 OR2W1 0.889
OR52D1 0.171
OR1A1 0.358
OR1A2 0.748
1-octanol OR1G1 0.512 OR5P3 3.458
OR52D1 0.512
OR2W1 0.826
OR1A1 1.013
OR1A2 2.051
OR51E1 2.425
OR2J2 3.458
Celeryketone OR1G1 0.171 OR5P3 1.225
OR2W1 0.287
OR1A1 0.358
OR1A2 0.748
Isovaleric acid OR1G1 0.171 OR51E1 0.883
OR52D1 0.171
OR117P 2.704
Propionic acid OR1G1 0.093 OR51E1 0.511
OR52D1 0.093
OR51E2 1.501
* To find ORs interacting to odorants, a neighbor protein procedure was used
which score the association between ORs and odorants. The lower is the score,
the stronger is the association.
doi:10.1371/journal.pone.0093037.t002
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Figure 5. Concentration-response curves of odorants for the human cannabinoid receptor CB1. Predicted compounds, tributyl acetyl
citrate, 2-nonanone and 2-phenylethyl hexanoate acted as inverse agonists. GloSensor assays were carried out in the absence (N) or in the presence
(#) of pertussis toxin-treated cells. Data points and EC50 values are means 6 s.e.m. from three experiments.
doi:10.1371/journal.pone.0093037.g005
Figure 6. Results of bio-activation of three odorants on the PPARc receptor. (a) Concentration dependent ligand displacement of three
odorants predicted as ligands for the PPARc receptor. (b) Transcriptional activation of PPARc by three odorants. Results are shown as the average 6
standard deviation of 2 individual experiments with each of the experiments performed with 8 replicas. Activation is given as fold activation relative
to the DMSO vehicle. Rosiglitazone (not shown) was used as positive control.
doi:10.1371/journal.pone.0093037.g006
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have an activity on PPARc seven fold better than naringenin
(IC50 = 1.2 mM). To assess the biological activities of these
compounds, activation of the PPARc ligand binding domain
(LBD) was investigated using trans-activation assays (see Methods
and SI). As a result, all three compounds were able to activate the
PPARc-LBD although with low efficiency (Figure 6b). The
apparent partial agonist properties of the compounds were
reflected by the ability to partly antagonize rosiglitazone-induced
transactivation in the same assay (data not shown). Overall, our
findings suggest that these compounds might have interesting anti-
diabetic and anti-inflammatory properties.
Discussion
Two approaches were developed in this study in order to
generate a human odorome: first, we identified some new odorant-
OR interactions as well as putative pathologies and pathways
associated to olfaction, and secondly, we proposed potential
therapeutic properties of a number of odorant molecules.
To start, we have developed an innovative approach for
predicting molecule candidates to hORs. Previous studies have
extensively used molecular structures of odorants and molecular
modeling to suggest such interactions [67–70]. The ability to make
new findings is illustrated by the development of a protein-protein
association network on ORs, which led to identification of new
ligand-OR interactions. As all models based on experimental data,
our proposed strategy is in a great dependence to the nature of
available data. We collected odorant that bind to ORs from public
available resources and negative control was not considered in our
model, which is unidirectional. One of the limitations is, only 24
human ORs showed bioactivity, which represent only 6% of the
human olfactome. Moreover we should take into consideration the
so-called ‘Matthew effect’ [71] resulting in maintained research
interest regarding already well-investigated odorants and ORs,
and then a larger amount of available data for these odorants and
ORs (OR1G1, OR52D1…). This skews the findings towards
interactions involving ORs already intensely investigated
(OR2W1). But this also highlights the ORs, which need further
attention. Hence the lack of predicted interaction between
odorants and OR5P3 for instance might be the result of less
available data to create the model rather than lack of biological
effect. The successful experimental validation on well-known OR
(OR2W1) and less-known OR (OR5P3) show the innovative level
of such computational approach.
The previous identification of targets repertoire is a crucial
importance, and could be very difficult to establish, especially in
the case of OR targets. Indeed, there is probably a gigantic
number of odorant molecules; some authors mention about
‘‘myriad of flavors’’, and Mori estimated ‘‘that more than 400 000
different compounds are odorous to the human nose’’ [23,72]. In
as much as a maximum of one hundred of molecules have been
tested on each expressed OR, it is difficult to ensure that the best
ligands of each studied OR have been identified [23]. Neverthe-
less, these data are now available and can be used for the
development of computational approaches able to decipher the
olfactory repertoire. For example, we could imagine that the
integration of negative data and degree of affinity of ligands to
ORs could be of great value in such OR-OR network.
From the OR-OR network, we proposed several associations
between odor and ORs. It is well admitted that an odor results
from the perception of a mixture of molecules. In other words,
odors described for example as ‘‘strawberry’’, ‘‘green’’ or ‘‘woody’’
have probably no real intrinsic existence, but report to some
environmental contexts. Consequently, humans need a lot of
words related to their contextual memories, to give full account of
their own perception, [73–75]. That may explain why the odor of
a molecule is rarely described by a sole odorant note but rather by
several notes. Each odor described by humans could be more
adequately defined as an ensemble of several ‘‘components’’.
Moreover, as the perception of odors results from a combinatorial
coding, this implies the unlikelihood to associate strictly an odor to
a sole receptor. Conversely, an OR might be associated to a
component of an odor.
In addition to the OR-OR network, integration of the
interactome and phenotypic data in the network allowed for a
second level of prediction capability. Disease gene candidates can
be prioritized, highlighting the potential role of the olfactory
system as a biomarker for diseases.
The second aspect of our work was to obtain an overview of drug-
targets (i.e. proteins) interacting with odorant molecules by
systematic structural similarity searches using a large chemoge-
nomic repository. Such exploration of the pharmacological space
was previously reported for drug compounds [76], characterized by
drug-protein associations. Up to now, no investigation has been
reported in the literature regarding large set of odorants. The in vitro
validation of predicted odorant binding to CB1 and PPARc
supports the possible pharmacological relevance of the newly
identified odorant-target relationships, although further studies are
necessary to gain more insight into the diffusion and the
biotransformation routes of such compounds to reach these targets.
Expanding the knowledge of our sense of smell by integrating
systems chemical biology of odorant molecules in drug discovery is
an attractive way to move forward in the quest to identify effective
drug-food combination therapies [77]. Recently, the development
of an electronic nose to detect signals associated with odorant
binding to GPCRs has shown promising results. Such artificial
nose technology detects and discriminates between odorants they
previously ‘‘learned’’ [78]. The combination of such technology
with computational biology represents an attractive strategy for
improving our knowledge of the molecular mechanisms of these
volatile molecules. Information on the olfactory system, the
pharmacology profile of individual odorants, the network regula-
tion as well as the pharmacodynamic, toxicological and pharma-
cokinetic effects is sparse and further investigations must be
performed. The pharmacological space of odorant molecules is not
exclusively limited to GPCRs (although they are in majority).
Direct pathway via the ORs, becoming activated by odorants after
nasal inhalation in the nose epithelium is well established [79].
Transcellular penetration into the central nervous system by
passive diffusion has also been described [80]. Therefore, we could
assume that such volatile compounds are not only stimulators of
olfactory perception but may be involved in other essential
physiological functions related to human health.
Supporting Information
Figure S1 Global mapping of the human odorome.
Nodes represent olfactory receptors (ORs) with known binding
ligands. Green nodes are human ORs, and blue nodes represent
human homologous and orthologous ORs derived from mouse
and rat information. The width of the edges correspond to the to
the weighted score.
(TIFF)
Figure S2 Mapping of odorants on the pharmacological
space. Chemical pair-wise similarity network based on the
chemical structure and using a Tanimoto coefficient threshold to
0.9. The blue nodes represent compounds with known bioactivity
from ChemProt and the green nodes are the odorants from
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FlavorBase. Edges represent a high structural similarity between
two molecules. The edge color indicates the Tanimoto values:
orange for Tc between 0.9 and 0.95 and purple for Tc between
0.95 and 1. From such graph, we can assume that an odorant (in
green) similar to a compound from ChemProt (in blue) potentially
shared the same bioactivity.
(TIFF)
Figure S3 Protein family distribution. The values indicate
the number of predicted interactions between odorant molecules
and proteins. Only families with more than 100 interactions are
shown separately, ‘other families’ represent the rest in the graph.
This other category contains for example the tyrosinase family, the
adenylate kinase family and glycogen phosphorylase family.
(TIFF)
Figure S4 Concentration-response curves of know li-
gands of human cannabinoid receptor CB1. As expected,
AEA and HU210 act as agonists whereas AM251 acts as inverse
agonist. GloSensor assays were carried out in the absence (N) or in
the presence (#) of pertussis toxin-treated cells. Data points and
EC50 values are means 6 s.e.m. from three experiments.
(TIFF)
File S1 Combined supporting information file contain-
ing Tables S1–S4 and Methods S1. Table S1: List of sources
used to gather odorant molecule-OR interactions. Table S2: List
of odor tendencies for the human olfactory receptors used in the
OR-OR network. Table S3: Diseases and biological pathways
linked to the olfactory system. Table S4: Odorant-OR interactions
in Human, Rat and Mouse.
(DOC)
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